Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg

Inclusion Criteria: 1. Healthy adults aged 19 and above with body mass index(BMI) between 18.5 and 30.0 kg/m2 2. Acceptable medical history, physical examination and laboratory tests during screening 3. Subjects who has signed a written informed consent voluntarily, prior to any procedure, using a form that is approved by the local Institutional Review Board after detailed explanation of the purpose, contents, and characteristic of the drug Exclusion Criteria: 1. History of clinically significant disease 2. Administration of ETC(ethical-the-counter drug) within 2 weeks or OTC(over-the-counter drug) within 1 week prior to the first dosing 3. Have AST(GOT) and/or ALT(GPT) and/or GGT(γGT) and/or Total Bilirubin \> 1.5 times of normal upper limit 4. Volunteers considered not eligible for the clinical trial by the investigator 5. Administration of other investigational products within 6 months prior to the first dosing